AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors

Epidermal growth factor receptor (EGFR) is overexpressed in up to 90% of head and neck squamous cell carcinoma (HNSCC) tumors. Cetuximab is the first targeted (anti-EGFR) therapy approved for the treatment of HNSCC patients. However, its efficacy is limited due to primary and secondary resistance, a...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Silva-Oliveira, Renato José, Melendez, Matias, Martinho, Olga, Zanon, Maicon F., de Souza Viana, Luciano, Carvalho, André Lopes, Reis, Rui Manuel
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2017
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5581110/
https://ncbi.nlm.nih.gov/pubmed/28881811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18395
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg